Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 2292 · Over-the-Counter Monograph Drug User Fee Amendments ·

Reported by committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 355 New drugs

+34 −0Shown
More for 21 U.S.C. § 355
Read § 355Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) is amended by adding at the end the following:(7) Rx-to-nonprescription switches.— (A) Meetings.— Any person planning to submit an application for an Rx-to-nonprescription switch may submit to the Secretary a written request for a meeting, for purposes of developing a plan for such application that addresses the potential …

    The section already has a provision under this letter or number, so it would have two.

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

§ 355(b)–(c)

Start of § 355 to (b)(7)(E) unchanged ·

(i) supersede or modify the authority of the Secretary under section 355h of this title with respect to the regulation of OTC monograph drugs; or

(ii) authorize the disclosure by the Secretary of confidential commercial information or trade secrets.

(7) [inserted: Rx-to-nonprescription switches.—]

(A) [inserted: Meetings.—] [inserted: Any person planning to submit an application for an Rx-to-nonprescription switch may submit to the Secretary a written request for a meeting, for purposes of developing a plan for such application that addresses the potential risks to public health of such switch and the evidence necessary to support such application, including the design of any necessary studies, and the format and content of the planned application. The Secretary may grant such a meeting, as appropriate, consistent with established procedures for granting meetings with, and providing written responses to, sponsors of applications under this section. Each such meeting shall be documented in meeting minutes.]

(B) [inserted: Guidance.—]

(i) [inserted: In general.—] [inserted: Not later than 18 months after the date of enactment of this paragraph, the Secretary shall issue guidance to increase the clarity and predictability of the process and standards for approval of applications for nonprescription drugs under this section, including in the case of applications for an Rx-to-nonprescription switch, especially with respect to prescription drugs with well-established safety profiles for which an applicant may seek approval for nonprescription use.]

(ii) [inserted: Contents.—] [inserted: The guidance under clause (i) shall—]

(I) [inserted: describe how published reports in medical literature, any previous finding of safety or effectiveness for the drug under this section, the results of significant human experience with the drug, unpublished studies and other data, and other sources of information may be used to support an application for a nonprescription drug, including in the context of an application for an Rx-to-nonprescription switch;]

(II) [inserted: set forth procedures for sponsors to request meetings described in subparagraph (A) and document the recommendations made in such meetings;]

(III) [inserted: describe evidentiary expectations to support approval of an application for a nonprescription drug, including in the context of an application for an Rx-to-nonprescription switch, including how sponsors can demonstrate that consumers can appropriately self-select and use the drug and comprehend the nonprescription drug label; and]

(IV) [inserted: provide recommendations for how mechanisms, in addition to the required Drug Facts Label, such as mobile applications and decision aids, can be incorporated into the information submitted in support of an application for an Rx-to-nonprescription switch.]

(C) [inserted: Plan to engage with stakeholders.—] [inserted: Not later than 1 year after the date of enactment of this paragraph, the Secretary shall develop and make publicly available on the website of the Food and Drug Administration a plan to engage stakeholders on steps and factors for application holders and other stakeholders to consider in identifying approved prescription drugs that may be promising candidates for applications for an Rx-to-nonprescription switch.]

(D) [inserted: Definition.—] [inserted: The term “Rx-to-nonprescription switch” means the approval of an application, or supplemental application, as applicable, submitted under this section by the holder of an approved application for a prescription drug seeking approval to market such drug as a nonprescription drug, including for—]

(i) [inserted: a full Rx-to-nonprescription switch, under which a drug previously approved for prescription use only is—]

(I) [inserted: approved for nonprescription use under the same conditions of use as applied to the drug when approved for prescription use; or]

(II) [inserted: approved for nonprescription use subject to one or more additional conditions for nonprescription use; and]

(ii) [inserted: a partial Rx-to-nonprescription switch, under which the drug is approved for nonprescription use only under certain conditions of use described in the approved labeling, while the drug otherwise remains approved for prescription use only.]

(E) [inserted: Rule of construction.—] [inserted: Nothing in this paragraph shall be construed to—]

(i) [inserted: supersede or modify the authority of the Secretary under section 505G with respect to the regulation of OTC monograph drugs; or]

(ii) [inserted: authorize the disclosure by the Secretary of confidential commercial information or trade secrets.]

(c) Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order

(1) Within one hundred and eighty days after the filing of an application under subsection (b), or such additional period as may be agreed upon by the Secretary and the applicant, the Secretary shall either—

Rest of § 355 unchanged ·

21 U.S.C. § 355h Regulation of certain nonprescription drugs that are marketed without an approved drug application

+14 −0Shown
More for 21 U.S.C. § 355h
Read § 355hOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 505G of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355h) is amended by adding at the end the following:(r) Evidence and testing standards for active ingredients for topical administration.— (1) Evidence and testing standards for active ingredients for topical administration.— The Secretary shall— (A) in evaluating the generally recognized as safe and effective status of active …

    The section already has a provision under this letter or number, so it would have two.

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

§ 355h(r)–(r)

Start of § 355h to (r)(2)(A) unchanged ·

(B) Guidance Not later than 1 year after November 12, 2025, the Secretary shall issue new draft guidance on how sponsors can use nonclinical testing alternatives to animal testing, as appropriate, to meet safety and efficacy standards under this section for drugs intended for topical administration.

(3) Clarification Nothing in this subsection shall be construed to alter, supersede, or limit the standards for making determinations of whether a drug is generally recognized as safe and effective under section 321(p) of this title or the standards set forth under section 355 of this title for determining the safety and effectiveness of drugs.

(r) [inserted: Evidence and testing standards for active ingredients for topical administration.—]

(1) [inserted: Evidence and testing standards for active ingredients for topical administration.—] [inserted: The Secretary shall—]

(A) [inserted: in evaluating the generally recognized as safe and effective status of active ingredients used in nonprescription drugs intended for topical administration for purposes of subsection (a), utilize standards that allow for the use of real world evidence (as defined in section 505F(b)), as appropriate, as part of a comprehensive evaluation of scientific evidence to demonstrate the safety and effectiveness of such active ingredients, to supplement evidence from traditional clinical trials, provided that such standards allow the Secretary to evaluate whether the benefits of such active ingredients outweigh the risks; and]

(B) [inserted: apply subsection (b)(6)(C) to the regulation of active ingredients used in drugs intended for topical administration.]

(2) [inserted: Non-animal testing methods for topical active ingredients.—]

(A) [inserted: In general.—] [inserted: The Secretary shall consider the types of nonclinical tests described in paragraphs (1) through (4) of the first subsection (z) of section 505 (as inserted by section 3209(a)(2) of the Health Extenders, Improving Access to Medicare, Medicaid, and CHIP, and Strengthening Public Health Act of 2022 (division FF of Public Law 117–328)), or any other alternative to animal testing that the Secretary determines appropriate, in the consideration of drugs intended for topical administration under this section.]

(B) [inserted: Guidance.—] [inserted: Not later than 1 year after the date of enactment of this subsection, the Secretary shall issue new draft guidance on how sponsors can use nonclinical testing alternatives to animal testing, as appropriate, to meet safety and efficacy standards under this section for drugs intended for topical administration.]

(3) [inserted: Clarification.—] [inserted: Nothing in this subsection shall be construed to alter, supersede, or limit the standards for making determinations of whether a drug is generally recognized as safe and effective under section 201(p) or the standards set forth under section 505 for determining the safety and effectiveness of drugs.]

21 U.S.C. § 379j–71 Definitions

+1 −11 of 4 shown
More for 21 U.S.C. § 379j–71
Read § 379j–71Only this section
4 changes the bill asks for here, 1 carried out
  1. Not carried out:

    in clause (v), by striking ; or and inserting a semicolon;

    “; or” isn't in § 379j–71(9)(A)(v) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“; or” not found in /us/usc/t21/s379j–71/9/A/v
  2. Not carried out:

    by striking addition and inserting the addition; and

    The law already reads this way: § 379j–71(9)(A)(vi) already has “the addition”.

    Technical detailalready reads “the addition” in /us/usc/t21/s379j–71/9/A/vi
  3. Carried out:

    by striking the period and inserting ; or; and

  4. Not carried out:

    by adding at the end the following:(vii) the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is— (I) established by a …

    The law already reads this way: § 379j–71(9)(A)(vii) is already as the bill would have it.

    Technical detailalready there: /us/usc/t21/s379j–71/9/A/vii reads as the bill would have it

2 of the 4 changes this bill asks for here are already in the law as it stands, and were not made a second time. The bill, or another making the same changes, has probably become law since.

§ 379j–71(9)(A)“Tier 2 OTC monograph order request” means…(v)–(vii)

Start of § 379j–71 to (9)(A)(iv) unchanged ·

(v) a change to ingredient nomenclature to align with nomenclature of a standards-setting organization;

(vi) the addition of an interchangeable term in accordance with section 330[struck: .1][inserted: ;] [inserted: or1 ]of title 21, Code of Federal Regulations (or any successor regulations); or

(vii) the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is—

(I) established by a national or international standards development organization; and

Rest of § 379j–71 unchanged ·

21 U.S.C. § 379j–72 Authority to assess and use OTC monograph fees

+18 −228 of 26 shown
More for 21 U.S.C. § 379j–72
Read § 379j–72Only this section
26 changes the bill asks for here, 8 carried out
  1. Not carried out:

    by striking on December 31 of the fiscal year or at any time during the preceding 12-month period and inserting at any time during the applicable period specified in clause (ii) for a fiscal year;

    “on December 31 of the fiscal year or at any time during the preceding 12-month period” isn't in § 379j–72(a)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“on December 31 of the fiscal year or at any time during the preceding 12-month period” not found in /us/usc/t21/s379j–72/a/1/A
  2. Not carried out:

    by striking Each person and inserting the following:(i) Assessment of fees.— Each person; and

    The law already reads this way: § 379j–72(a)(1)(A)(i) already sets these words apart as their own provision.

    Technical detailalready: /us/usc/t21/s379j–72/a/1/A/i holds the words already
  3. Not carried out:

    by adding at the end the following:(ii) Applicable period.— For purposes of clause (i), the applicable period is— (I) for fiscal year 2026, the 12-month period ending on December 31, 2025; (II) for fiscal year 2027, the 9-month period ending on September 30, 2026; and (III) for fiscal year 2028 and each …

    The law already reads this way: § 379j–72(a)(1)(A)(ii) is already as the bill would have it.

    Technical detailalready there: /us/usc/t21/s379j–72/a/1/A/ii reads as the bill would have it
  4. Carried out:

    in subparagraph (B)(i), by amending subclause (I) to read as follows:(I) has ceased all activities related to OTC monograph drugs prior to— (aa) for purposes of fiscal year 2026, January 1, 2025; (bb) for purposes of fiscal year 2027, January 1, 2026; and (cc) for purposes of fiscal year 2028 and each subsequent fiscal year, October 1 of the preceding fiscal year; and; and

  5. Carried out:

    by amending subparagraph (D) to read as follows:(D) Due date.— (i) Fiscal year 2026.— For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of— (I) the first business day of June of such year; or (II) the first business day after the enactment of an appropriations Act providing for …

  6. Carried out:

    Section 744M(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–72(b)) is amended to read as follows:(b) Fee revenue amounts.— (1) In general.— For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of— (A) the annual base revenue for the fiscal year (as determined under …

  7. Not carried out:

    by striking subsection (b)(2)(B) and inserting subsection (b)(1)(B); and

    “subsection (b)(2)(B)” isn't in § 379j–72(c)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“subsection (b)(2)(B)” not found in /us/usc/t21/s379j–72/c/1/A
  8. Not carried out:

    by striking fiscal year 2022 and each subsequent fiscal year and inserting each fiscal year;

    “fiscal year 2022 and each subsequent fiscal year” isn't in § 379j–72(c)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“fiscal year 2022 and each subsequent fiscal year” not found in /us/usc/t21/s379j–72/c/1/A
  9. Not carried out:

    in subparagraph (B), by striking fiscal year 2022 and all that follows through the period at the end and inserting the following:(i) for fiscal year 2026— (I) the fee for fiscal year 2025 under subsection (a)(2); and (II) the inflation adjustment percentage under subparagraph (C); and (ii) for each of fiscal years 2027 through 2030— (I) the applicable fee under subsection (a)(2) for the preceding fiscal …

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking QTEXT and all that follows through the period at the end and inserting the following: QCONTENT; and
  10. Not carried out:

    in the matter preceding clause (i), by inserting the sum of after is equal to;

    The law already reads this way: § 379j–72(c)(1)(C) already has “the sum of”.

    Technical detailalready reads “the sum of” at that place in /us/usc/t21/s379j–72/c/1/C
  11. Carried out:

    by striking clause (i);

  12. Not carried out:

    by redesignating subclauses (I) and (II) of clause (ii) as clauses (i) and (ii), respectively, and adjusting the margins accordingly;

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: redesignating subclauses (X) and (X) of clause (X) as clauses (X) and (X), respectively, and adjusting the margins accordingly;
  13. Not carried out:

    by striking (ii) for each of fiscal years 2024 and 2025, the sum of—; and

    “(ii) for each of fiscal years 2024 and 2025, the sum of—” isn't in § 379j–72(c)(1)(C) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“(ii) for each of fiscal years 2024 and 2025, the sum of—” not found in /us/usc/t21/s379j–72/c/1/C
  14. Not carried out:

    in clause (ii), as so redesignated, by striking Washington-Baltimore, DC–MD–VA–WV and inserting Washington–Arlington–Alexandria–DC–VA–MD–WV;

    “Washington-Baltimore, DC–MD–VA–WV” isn't in § 379j–72(c)(1)(C)(ii) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“Washington-Baltimore, DC–MD–VA–WV” not found in /us/usc/t21/s379j–72/c/1/C/ii
  15. Not carried out:

    by striking fiscal year 2021 and subsequent fiscal years and inserting each fiscal year;

    “fiscal year 2021 and subsequent fiscal years” isn't in § 379j–72(c)(2)(A) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“fiscal year 2021 and subsequent fiscal years” not found in /us/usc/t21/s379j–72/c/2/A
  16. Not carried out:

    by striking subsections (b)(1)(B) and (b)(2)(C) and inserting subsection (b)(1)(C); and

    “subsections (b)(1)(B) and (b)(2)(C)” isn't in § 379j–72(c)(2)(A) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“subsections (b)(1)(B) and (b)(2)(C)” not found in /us/usc/t21/s379j–72/c/2/A
  17. Not carried out:

    by striking the number of weeks specified in subparagraph (B) and inserting 10 weeks;

    “the number of weeks specified in subparagraph (B)” isn't in § 379j–72(c)(2)(A) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“the number of weeks specified in subparagraph (B)” not found in /us/usc/t21/s379j–72/c/2/A
  18. Carried out:

    by striking subparagraph (B);

  19. Carried out:

    by redesignating subparagraphs (C) and (D) as subparagraphs (B) and (C), respectively; and

  20. Not carried out:

    in subparagraph (C), as so redesignated, by striking paragraph (4) establishing and inserting paragraph (5) publishing;

    The bill points to subparagraph (C) of § 379j–72(c)(2), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no subparagraph (C) in /us/usc/t21/s379j–72/c/2
  21. Not carried out:

    in the matter preceding subparagraph (A), by striking subsection (b)(2)(D) and inserting subsection (b)(1)(D); and

    “subsection (b)(2)(D)” isn't in § 379j–72(c)(3) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“subsection (b)(2)(D)” not found in /us/usc/t21/s379j–72/c/3
  22. Carried out:

    by striking subparagraphs (A) through (E) and inserting the following:(A) $135,000 for fiscal year 2026; (B) $300,000 for fiscal year 2027; (C) $55,000 for fiscal year 2028; (D) $30,000 for fiscal year 2029; and (E) $0 for fiscal year 2030.; and

  23. Carried out:

    by striking paragraph (4) and inserting the following:(4) One-time facility fee workload adjustment.— (A) In general.— In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance …

  24. Not carried out:

    in the subparagraph heading, by striking in subsequent years; and

    “in subsequent years” isn't in § 379j–72(f)(2)(D) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“in subsequent years” not found in /us/usc/t21/s379j–72/f/2/D
  25. Not carried out:

    by striking (after fiscal year 2021); and

    “(after fiscal year 2021)” isn't in § 379j–72(f)(2)(D) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“(after fiscal year 2021)” not found in /us/usc/t21/s379j–72/f/2/D
  26. Not carried out:

    in paragraph (3), by striking 2021 through 2025 and inserting 2026 through 2030.

    “2021 through 2025” isn't in § 379j–72(f)(3) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“2021 through 2025” not found in /us/usc/t21/s379j–72/f/3

3 of the 26 changes this bill asks for here are already in the law as it stands, and were not made a second time. The bill, or another making the same changes, has probably become law since.

§ 379j–72(a)(1)Facility fee(B)–(D)

Start of § 379j–72 to (a)(1)(B)(i)(II) unchanged ·

(ii) Contract manufacturing organizations The amount of the fee for a contract manufacturing organization facility shall be equal to two-thirds of the amount of the fee for an OTC monograph drug facility that is not a contract manufacturing organization facility.

(C) Amount The amount of fees established under subparagraph (A) shall be established under subsection (c).

(D) Due date[inserted: .—]

(i) Fiscal year 2026[inserted: .—] For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of—

(I) the first business day of June of such year; or

(II) the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year.

(ii) Fiscal year 2027[inserted: .—] For fiscal year 2027, the facility fees required under subparagraph (A) shall be due—

(I) in a first installment representing 50 percent of such fee, on the later of—

§ 379j–72(a)(1)(D)Due date.—(ii)–(iii)

(a)(1)(D)(ii)(I)(aa)–(II) unchanged ·

(aa) February 1, 2027; or

(bb) if an appropriations Act described in subclause (I)(bb) is not in effect on February 1, 2027, the first business day after enactment of such an appropriations Act.

(iii) Subsequent fiscal years[inserted: .—] For fiscal year 2028 and each subsequent fiscal year, the facility fees required under subparagraph (A) shall be due on the later of—

(I) the first business day on or after October 1 of the fiscal year; or

§ 379j–72(a)–(b)

(a)(1)(D)(iii)(II)–(3)(A) unchanged ·

(B) Disputes concerning fees To qualify for the return of a fee claimed to have been paid in error under paragraph (1) or (2), a person shall submit to the Secretary a written request justifying such return within 180 calendar days after such fee was paid.

(4) Notice Within the timeframe specified in subsection (c), the Secretary shall publish in the Federal Register the amount of the fees under paragraph (1) for such fiscal year.

(b) Fee revenue amounts[inserted: .—]

(1) In general[inserted: .—] For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—

(A) the annual base revenue for the fiscal year (as determined under paragraph (2));

§ 379j–72(b)–(c)

(b)(1)(B)–(E) unchanged ·

(iii) $854,000 for fiscal year 2028; and

(F) in the case of a fiscal year for which the Secretary applies the one-time facility fee workload adjustment under subsection (c)(4), the dollar amount equal to such adjustment.

(2) Annual base revenue[inserted: .—] For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be—

(A) for fiscal year 2026, the dollar amount of the total revenue amount established for fiscal year 2025 under this subsection as in effect on the day before [struck: November][inserted: the] [struck: 12,][inserted: date] [struck: 2025][inserted: of enactment of the Over-the-Counter Monograph Drug User Fee Amendments], not including any adjustments made for such fiscal year 2025 under subsection (c)(2), as so in effect; and

(B) for fiscal years 2027 through 2030, the dollar amount of the total revenue amount established under this subsection for the previous fiscal year, not including any adjustments made for such previous fiscal year under subsection (c)(2) or (c)(3).

(c) Adjustments; annual fee setting

§ 379j–72(c)Adjustments; annual fee setting(1)–(4)

(c)(1) unchanged ·

(II) the inflation adjustment percentage under subparagraph (C).

(C) Inflation adjustment percentage The inflation adjustment percentage under this subparagraph for a fiscal year is equal to the sum of—

[struck: (i)] [struck: the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 years of the preceding 4 fiscal years, multiplied by the proportion of personnel compensation and benefits costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 fiscal years; and]

(ii) the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington–Arlington–Alexandria–DC–VA–MD–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 fiscal years.

(2) Operating reserve adjustment

(A) In general For each fiscal year, for purposes of subsection (b)(1)(C), the Secretary may, in addition to adjustments under paragraph (1), further increase the fee revenue and fees if such an adjustment is necessary to provide operating reserves of carryover user fees for OTC monograph drug activities for not more than 10 weeks.

[struck: (B)] [struck: Decrease] [struck: If the Secretary has carryover balances for such process in excess of 10 weeks of the operating reserves referred to in subparagraph (A), the Secretary shall decrease the fee revenue and fees referred to in such subparagraph to provide for not more than 10 weeks of such operating reserves.]

[struck: (C)] [inserted: (B)] Rationale for adjustment If an adjustment under this paragraph is made, the rationale for the amount of the increase or decrease (as applicable) in fee revenue and fees shall be contained in the annual Federal Register notice under paragraph (5) publishing fee revenue and fees for the fiscal year involved.

(3) Additional direct cost adjustment The Secretary shall, in addition to adjustments under paragraphs (1) and (2), further increase the fee revenue and fees for purposes of subsection (b)(1)(D) by an amount equal to—

(A) $135,000 for fiscal year 2026;

(B) $300,000 for fiscal year 2027;

(C) $55,000 for fiscal year 2028;

(D) [inserted: $30,000 for fiscal year 2029; and]

[struck: (D)] [struck: $30,000 for fiscal year 2029; and]

(E) $0 for fiscal year 2030.

(4) One-time facility fee workload adjustment[inserted: .—]

(A) In general[inserted: .—] In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance with this paragraph.

(B) Adjustment described[inserted: .—]

(i) Conditions for adjustment[inserted: .—] An adjustment under this paragraph may be made for a fiscal year only if—

(I) an adjustment under this paragraph had not been made for any prior fiscal year;

(II) the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the period of the preceding 3 fiscal years exceeds 1,625; and

(III) with respect to facilities described in subclause (II), the average number of such facilities (expressed as a percentage) that appeared on the arrears lists pursuant to subsection (e)(1)(A)(i) over the period of the preceding 3 fiscal years is less than 30 percent.

(ii) Amount of adjustment[inserted: .—] An adjustment under this paragraph for a fiscal year shall equal the product of—

(I) the total facility revenue amount determined under subsection (b) for the fiscal year, exclusive of the adjustment under this paragraph for such fiscal year; and

(II) the excess facility percentage described in clause (iii).

(iii) Excess facility percentage[inserted: .—] The excess facility percentage described in this clause is—

(I) the amount by which the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the preceding 3 fiscal years exceeds 1,625; divided by

Rest of § 379j–72 unchanged ·

21 U.S.C. § 379j–73 Reauthorization; reporting requirements

+38 −01 of 6 shown
More for 21 U.S.C. § 379j–73
Read § 379j–73Only this section
6 changes the bill asks for here, 1 carried out
  1. Not carried out:

    by striking Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter and inserting the following: (1) In general.— Not later than 120 calendar days after the end of each fiscal year;

    The law already reads this way: § 379j–73(a)(1) already sets these words apart as their own provision.

    Technical detailalready: /us/usc/t21/s379j–73/a/1 holds the words already
  2. Not carried out:

    by striking section 3861(b) of the CARES Act and inserting section 2 of the Over-the-Counter Monograph Drug User Fee Amendments; and

    “section 3861(b) of the CARES Act” isn't in § 379j–73(a) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“section 3861(b) of the CARES Act” not found in /us/usc/t21/s379j–73/a
  3. Carried out:

    by adding at the end the following:(2) Additional information.— Beginning with fiscal year 2026, the annual report under this subsection shall include— (A) the progress of the Food and Drug Administration in achieving the goals, and future plans for meeting the goals, including— (i) the number of Tier 1 OTC …

    The section already has a provision under this letter or number, so it would have two.

  4. Not carried out:

    in subsection (b), by striking fiscal year 2021 and each subsequent fiscal year and inserting each fiscal year; and

    “fiscal year 2021 and each subsequent fiscal year” isn't in § 379j–73(b) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“fiscal year 2021 and each subsequent fiscal year” not found in /us/usc/t21/s379j–73/b
  5. Not carried out:

    by striking 2025 each place it appears and inserting 2030; and

    “2025” isn't in § 379j–73(d) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“2025” not found in /us/usc/t21/s379j–73/d
  6. Not carried out:

    by adding at the end the following:(4) Minutes of negotiation meetings.— (A) Public availability.— The Secretary shall make publicly available, on the public website of the Food and Drug Administration, robust written minutes of all negotiation meetings conducted under this subsection between the Food and Drug …

    The law already reads this way: § 379j–73(d)(4) is already as the bill would have it.

    Technical detailalready there: /us/usc/t21/s379j–73/d/4 reads as the bill would have it

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

2 of the 6 changes this bill asks for here are already in the law as it stands, and were not made a second time. The bill, or another making the same changes, has probably become law since.

§ 379j–73(a)–(c)

Start of § 379j–73 to (a)(2)(C)(ii) unchanged ·

(D) the progress of the Food and Drug Administration in allowing nonclinical testing alternatives to animal testing for the consideration of sunscreen active ingredients.

(3) Confidentiality Nothing in paragraph (2) shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 331(j) of this title or section 1905 of title 18 or that is subject to withholding under section 552(b)(4) of title 5.

(2) [inserted: Additional information.—] [inserted: Beginning with fiscal year 2026, the annual report under this subsection shall include—]

(A) [inserted: the progress of the Food and Drug Administration in achieving the goals, and future plans for meeting the goals, including—]

(i) [inserted: the number of Tier 1 OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;]

(ii) [inserted: the number of Tier 2 OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;]

(iii) [inserted: the number of specified safety OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;]

(iv) [inserted: the number of generally recognized as safe and effective finalization OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;]

(v) [inserted: the average timeline for processing OTC monograph order requests, in the aggregate and by submission type, in the previous fiscal year; and]

(vi) [inserted: postmarket safety activities with respect to OTC monograph drugs, including—]

(I) [inserted: collecting, developing, and reviewing safety information on OTC monograph drugs, including adverse event reports;]

(II) [inserted: developing and using improved analytical tools, adverse event data-collection systems, including information technology systems, to assess potential safety problems, including access to external databases; and]

(III) [inserted: activities under section 760;]

(B) [inserted: information regarding registration of OTC monograph drug facilities and contract manufacturing organization facilities and payment of registration fees by such facilities, including—]

(i) [inserted: the OTC monograph drug facilities and contract manufacturing organization facilities that were first registered under section 510(c) or 510(i) in the fiscal year; and]

(ii) [inserted: for each OTC monograph drug facility and contract manufacturing organization facility that was assessed a facility fee under section 744M(a) in the fiscal year, whether the facility paid such fee;]

(C) [inserted: the status of implementation of evidence and testing standards for nonprescription drugs intended for topical administration, including—]

(i) [inserted: the application of evidence or testing standards; and]

(ii) [inserted: the number of active ingredient requests for nonprescription drugs intended for topical administration reviewed using the standards under section 505G(b); and]

(D) [inserted: the progress of the Food and Drug Administration in allowing nonclinical testing alternatives to animal testing for the consideration of sunscreen active ingredients.]

(3) [inserted: Confidentiality.—] [inserted: Nothing in paragraph (2) shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 301(j) of this Act or section 1905 of title 18, United States Code, or that is subject to withholding under section 552(b)(4) of title 5, United States Code.]

(b) Fiscal report Not later than 120 calendar days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.

(c) Public availability The Secretary shall make the reports required under subsections (a) and (b) available to the public on the internet website of the Food and Drug Administration.

Rest of § 379j–73 unchanged ·

Step through the changes